---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-084538"
form_type: "8-K"
ticker: null
cik: "0001442836"
company_name: "Mersana Therapeutics, Inc."
filed_at: "2023-07-27T23:59:59+00:00"
generated_at: "2026-06-13T00:17:55.214418+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Mersana Therapeutics fails Phase 2 UPLIFT trial; cuts workforce 50% and shifts focus to next-gen ADC platforms

## Summary
- UPLIFT trial of UpRi in platinum-resistant ovarian cancer missed primary endpoint; ORR 15.6% in NaPi2b-positive patients (95% CI: 10.0%-22.7%).
- Company to discontinue UpRi development, wind down related trials (UP-NEXT, UPGRADE-A), and reduce staffing by ~50%.
- Preliminary cash balance of $286.6M as of June 30, 2023; expects funds to support operating plan into 2026.
- Focus shifts to next-generation ADC platforms Dolasynthen and Immunosynthen; plans to advance XMT-1660 and address XMT-2056 clinical hold.

## SEC filing metadata
- accession: 0001104659-23-084538
- form_type: 8-K
- cik: 0001442836
- company_name: Mersana Therapeutics, Inc.
- filed_at: 2023-07-27T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 2.05, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1442836/000110465923084538/0001104659-23-084538-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1442836/000110465923084538/tm2322196d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-084538
- JSON: https://secwatch.observer/filing/0001104659-23-084538.json
- Plain text: https://secwatch.observer/filing/0001104659-23-084538.txt

## Key facts
- Earnings Releases
  Mersana Therapeutics, Inc. reported preliminary financial results for the three and six months ended June 30, 2023.
  - Period: the three and six months ended June 30, 2023
  - Result: preliminary results
  source text: Although the Company has not finalized its financial results for the three and six months ended June 30, 2023, the Company preliminarily estimates that its cash, cash equivalents and marketable securities as of June 30, 2023 was $286.6 million.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1442836/000110465923084538/0001104659-23-084538-index.htm
- Restructurings & Charges
  Mersana Therapeutics, Inc. announced a restructuring with charges of approximately $7-8 million affecting UpRi clinical program and companywide operations (approximately 50% of the Company's current employee base).
  - Type: restructuring
  - Charge: approximately $7-8 million
  - Affected area: UpRi clinical program and companywide operations
  - Headcount: approximately 50% of the Company's current employee base
  source text: On July 27, 2023, the Company announced decisions to reprioritize its areas of focus and to discontinue its clinical development of upifitamab rilsodotin (“UpRi”) following an evaluation of top-line data from the Company’s UPLIFT Phase 2 clinical trial of UpRi in patients with platinum-resistant ovarian cancer, which did not meet its primary endpoint. In connection with these decisions, on July 26, 2023, the Company’s board of directors approved certain expense reduction measures, including a reduction of approximately 50% of the Company’s current employee base (the “Restructuring”). The Restructuring is expected to be complete by the end of 2023. As a result of the Restructuring, the Company estimates that it will incur approximately $7-8 million in costs resulting from cash expenditures consisting of severance and benefit payments, notice pay, outplacement services and related expenses.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1442836/000110465923084538/0001104659-23-084538-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.